Classification
MDS is classified according to the WHO classification, an updated version was published in 2016. Use the updated version to define the specific subtype of MDS and send this information to the New Zealand Cancer Registry (NZCR) for all new diagnoses. See Diagnosis for the diagnostic criteria.
Changes in the 2016 guidelines include:
- The dysplastic lineage ("MDS with single lineage dysplasia" or "MDS with multilineage dysplasia") is now described, rather than the cytopenic lineage ("refractory anaemia" in the 2008 classification).
- An updated definition of chronic myelomonocytic leukaemia (CMML) to include a new category of CMML-0 (<2% blasts in the blood, <5% blasts in the bone marrow).
- MDS with del(5q) can be made if there is one single additional cytogenetic abnormality (with the exception of monosomy 7 or del(7q).
- The new diagnosis "MDS/MPN with ring sideroblasts and thrombocytosis" replaces "refractory anaemia with ring sideroblasts with thrombocytosis (RARS-T)".
WHO classification of myeloid neoplasms and acute leukaemia (2016)
Myelodysplastic syndromes (MDS)
- MDS with single lineage dysplasia
- MDS with ring sideroblasts (MDS-RS)
- MDS-RS and single lineage dysplasia
- MDS-RS and multilineage dysplasia
- MDS with multilineage dysplasia
- MDS with excess blasts
- MDS with isolated del(5q)
- MDS, unclassifiable
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
- Chronic myelomonocytic leukaemia (CMML)
- Atypical chronic myeloid leukaemia (aCML) BCR-ABL 1-
- Juvenile myelomonocytic leukaemia (JMML)
- MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPS-RS-T)
- MDS/MPN unclassifiable
Topic Code: 4954
Disclaimer